

## JAPANESE PATENT ISSUED IN CORE BARD1 PATENT FAMILY

- **Divisional Japanese Patent no P6271636 issued**
- **Patent provides additional protection for prevention or treatment of lung and colorectal cancer**

**Perth, Australia, 2 February 2018:** BARD1 Life Sciences Limited (ASX:BD1), a biotechnology company developing non-invasive cancer diagnostics, today announced that on 12<sup>th</sup> January 2018, Japan Patent Office issued Japanese Patent number P6271636 (Divisional of JP P5938406) titled “BARD1 isoforms in lung and colorectal cancer and use thereof”.

This patent family protects the sequence of various BARD1 isoforms specific to lung and colorectal cancer, a method for detecting the presence of the specific BARD1 isoforms, and a method for treating and/or preventing lung cancer and colorectal cancer.

Japanese Patent number P6271636 provides additional protection over the parent case P5938406 for modulators such as siRNA molecules of specific BARD1 isoforms for use in treatment or prevention of lung or colorectal cancer. This patent was filed in the name of Université De Genève (UNIGE) and Hôpitaux Universitaires de Genève (HUG) on 17 August 2011 and is due to expire on 17 August 2031. BARD1 LSL (via its fully owned subsidiary BARD1AG SA) has licensed the commercial rights to exploit this technology from UNIGE and HUG.

- ENDS -

### FOR MORE INFORMATION PLEASE CONTACT:

**Peter Gunzburg**  
Chairman  
E [peter@bard1.com](mailto:peter@bard1.com)

**Dr Leearne Hinch**  
CEO  
E [leearne@bard1.com](mailto:leearne@bard1.com)  
M +61 400 414 416

### ABOUT BARD1 LIFE SCIENCES LTD (BARD1 LSL)

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian-based biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1's proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The development pipeline includes two BARD1 autoantibody tests in early development for early detection of lung and ovarian cancers, and a cancer vaccine project at research-stage for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients' lives. For more information on BARD1, see [www.bard1.com](http://www.bard1.com).

### ABOUT THE BARD1 INTELLECTUAL PROPERTY PORTFOLIO

BARD1 has established a strong intellectual property position covering various BARD1 DNA and protein sequences, methods of diagnosis and treatment, and use in multiple cancers. The patent portfolio comprises 5 patent families with multiple granted and pending patents across key marketplaces including the US, Europe and Japan. In addition, the algorithms are protected by trade secret.

Patent Family	Title	Granted	Pending	Expiry
PCT/FR01/02731	Truncated BARD1 protein and its diagnostic and therapeutic uses	US, JP		2023*
PCT/IB2011/053635	BARD1 isoforms in lung and colorectal cancer and use thereof	US, JP, JP div, CN, AU	US, CN (divisionals), EP, CA, IL, BR, SG, HK	2031*
PCT/IB2011/054194	Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof		US, EP	2032*
PCT/EP2014/073834	Lung Cancer Diagnosis		US, EP, CA, JP, IL, CN, AU, SG, KR, HK	2034*
EP14002398.7	Novel non-coding RNA, cancer target and compounds for cancer treatment		US	2035*

\* Plus any extension of term in the US due to prosecution delay